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The physical health of people with serious mental illness is an issue of major concern to 
individuals, their families, clinicians and healthcare policy-makers (The Schizophrenia 
Commission, 2012). Mortality rates remain around twice those found in the general 
population (Saha et al., 2007) with high levels of cardiovascular disease (Goff et al., 2005), 
metabolic disease (De Hert et al., 2006), diabetes (Newcomer et al., 2002), and respiratory 
illness (Chafetz et al., 2008). Clozapine has been shown to be the most effective 
medication for treatment-resistant schizophrenia (Essali et al., 2009) but has important 
side-effects, with higher rates of agranulocytosis, weight gain, metabolic syndrome, 
hyperglycaemia, and hypertension (Drew, 2013). We aimed to use a health informatics 
approach with routinely-collected data to determine the prevalence of glucose 
dysregulation, diabetes mellitus, and treatment levels for diabetes in clozapine-treated 
patients with schizophrenia. 
 
We used electronically-linked data from the Glasgow Psychosis Clinical Information 
System (PsyCIS) of around 8,910 patients with serious mental illness (predominantly 
psychotic disorders) that have been systematically registered over the last 10 years. From 
this group we identified 1,157 individuals receiving clozapine medication (836 (72.7%) 
male and 314 (27.2%) female) (Table 1). We then estimated the prevalence of diabetes by 
firstly identifying patients with a raised plasma glucose (>11.1 mmol/l) or HbA1c (>48 
mmol/l), and then finding a second confirmatory test to meet the diagnostic criteria (WHO, 
2011).  We found that in total 1,086 patients (94%) had a record of screening with at least 
one routine glucose test, 635 (55%) had a recorded glycosylated haemoglobin test, and 
1,063 (92%) had plasma cholesterol levels recorded (Table 1).  One hundred and seventy-
five clozapine-treated patients (15.1%) met criteria for diabetes mellitus using plasma 
glucose measurement, compared to a proportion of 5.8% in the general population (z=11.9, 
p=0.001). A diagnosis of diabetes mellitus using HbA1c was found in 168 patients (14.4%) 
but screening for HbA1c was only conducted in 635 individuals. The prevalence of 
diabetes was higher in men (67.4% 118/175) than in women but this difference was not 
significant (χ²=2.6, p=0.11). The prevalence of diabetes increased with age to a peak at age 
group 40-49 (χ²=38.9, p=0.001).  
 
Twenty percent of clozapine-treated patients were prescribed a second antipsychotic 
medication, predominantly amisulpiride and a higher risk of diabetes was associated with 
the prescription of a second antipsychotic medication (χ²=190.2, p=0.001). There was a 
small association between the risk of diabetes and duration of clozapine treatment (OR 
1.08, 95% CI 1.02-1.13, z=2.66, p=0.008) but the prevalence of diabetes was not 
associated with clozapine dose (OR 1.00, 95% CI 0.998-1.000, z=-0.83, p=0.404), or levels 
of socioeconomic deprivation (χ²=6.97, p=0.14).  
 
Seventy percent of clozapine-treated patients with diabetes received at least one 
antidiabetic medication, which was usually metformin (62.9%).  In those for whom HbA1c 
data were available, the control of diabetes appeared to be poor, with a mean (initial) 
HbA1c of 66.98 mmol/l (SD +20.84, 95% CI 63.80-70.16), well above the recommended 
level of >48mmol/l.  
 
We have identified levels of diabetes of 15% in what is the largest single sample of 
clozapine-treated patients reported to date. Earlier studies have found different estimates of 
diabetes, from 6% in patients attending a psychiatric outpatient clinic (Sernyak et al., 2003) 
to 22% within an inpatient psychiatric hospital setting (Zhang et al., 2011). Electronic 
linkage of routine data may have identified individuals with diabetes who would have 
previously remained undiagnosed. This approach may also have helped to avoid the 
recognised problems of health screening in people with serious mental illness, such as poor 
access to medical care and low engagement with preventative interventions. 
 
We recognise that a small proportion of patients may have received blood sampling or 
treatment elsewhere and that we may have potentially missed some individuals who had 
been diagnosed with diabetes and successfully treated.  We were not able to identify other 
risk factors which may have contributed to diabetes risk, such as weight problems, poor 
diet, or lack of physical activity. 
 
Explanations for the high levels of diabetes in people with serious mental illness remain 
unclear, but are likely to be multi-factorial. These include hereditary factors and 
environmental influences, such as unhealthy lifestyles with weight gain, poor daily dietary 
intake, and a sedentary lifestyle. We propose that the electronic linkage of routinely 
collected clinical data has considerable potential to improve the detection and treatement of 
medical comorbidities in individuals with severe mental illness.   
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Table 1. Summary Characteristics of Patients Treated with Clozapine  
 
Characteristics                                                       N       %         Mean     SD       Min   Max        
 
     Total No of Patients                                            1157                                                 
      Mean Age (yrs)                                                  1157                45.86     11.3       18       84                       
      Age Group (yrs)             
           Years                                                                         
 16- 20                                                                 3       0.3             
 21- 30                                                               87       7.6             
 31- 39                                                             249     21.6            
 40- 49                                                             371     32.3            
 50- 59                                                             319     27.7   
 60- 69                                                             100       8.7 
 70- 79                                                               20       1.7        
 80+                                                                     1       0.1                         
      Sex  
Female                                                           314       27.2 
Male                                                               841      72.8 
 
Total Baseline Blood Measurements                   
HbA1C                                                            635      55.0    43.10       14.0     25.0     140.0       
Glucose                                                         1086      94.0      6.56       2.92       2.6       33.2   
Cholesterol                                                    1063      92.0      5.22       1.31       1.8       14.0 
HDL                                                                 1026      88.7      1.08       0.32        0.2         
3.6 
LDL                                                                 825      71.3      3.07       1.07       0.4         7.0 
Chol/HDL Ratio                                              999      86.3      5.08       1.79       1.8       20.5  
Triglycerides                                                   1058      91.4      2.44       1.69        0.4       16.6 
 
Cholesterol >5.0                                              610      52.7      6.09       0.96       5.0       14.0   
HDL (< 1 mmol/l)                                           513      44.3      0.84       0.13       0.2         1.0 
LDL (> 3.0 mmol/l)                                        427      36.9      3.89       0.75       3.0         7.0 
 
Clozapine 
Clozapine Dose (mg/d)                                                         385.2     163.4       6.25      900 
Clozapine Duration (yrs)                                                          7.1       3.16        0.3       18.9  
 
 
 
 
